Search Results

Kiromic BioPharma, Inc. announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel ™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Predictive Oncology Inc. announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.

Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, announced the live deployment by the University of Pittsburgh Medical Center of Galen™ Prostate, an AI-based solution that supports pathologists during cancer diagnosis, at the UPMC network.

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women’s Hospital, Champalimaud Foundation and Ohio State University (OSU).

As part of its commitment to investing in translational science that significantly improves the lives of patients, UPMC has launched Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer.

ECM Therapeutics announces a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine.

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and their functions in the body can effectively be used in clinical care.

Harvard Apparatus Regenerative Technology, Inc. announced that it officially executed a sponsored research agreement with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.

AIM ImmunoTech Inc. today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC”) has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.